Trial Profile

An Open Label, Single Arm, Multicenter Phase Ⅰb/Ⅱ Clinical Study of Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fruquintinib (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Toripalimab (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Adverse reactions; Therapeutic Use

20 Jan 2024 Results (at data cut-off August 31, 2023, n= 17 pts) assessing safety and efficacy of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma presented at the 2024 Gastrointestinal Cancers Symposium.
09 Feb 2022 Status changed from not yet recruiting to recruiting.
08 Feb 2022 Planned End Date changed from 1 Oct 2024 to 1 Feb 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com